MA55347A - Anticorps anti-lag3 et fragments de fixation à l'antigène - Google Patents
Anticorps anti-lag3 et fragments de fixation à l'antigèneInfo
- Publication number
- MA55347A MA55347A MA055347A MA55347A MA55347A MA 55347 A MA55347 A MA 55347A MA 055347 A MA055347 A MA 055347A MA 55347 A MA55347 A MA 55347A MA 55347 A MA55347 A MA 55347A
- Authority
- MA
- Morocco
- Prior art keywords
- antigen binding
- binding fragments
- lag3 antibodies
- lag3
- antibodies
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462039081P | 2014-08-19 | 2014-08-19 | |
US201562171319P | 2015-06-05 | 2015-06-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55347A true MA55347A (fr) | 2022-01-26 |
Family
ID=53938468
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40476A MA40476B1 (fr) | 2014-08-19 | 2015-08-17 | Anticorps et fragments de fixation à l'antigène anti-lag3 |
MA055347A MA55347A (fr) | 2014-08-19 | 2015-08-17 | Anticorps anti-lag3 et fragments de fixation à l'antigène |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40476A MA40476B1 (fr) | 2014-08-19 | 2015-08-17 | Anticorps et fragments de fixation à l'antigène anti-lag3 |
Country Status (40)
Families Citing this family (237)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008266951B2 (en) | 2007-06-18 | 2013-12-12 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor PD-1 |
ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
EP2943511B1 (fr) | 2013-01-14 | 2019-08-07 | Xencor, Inc. | Nouvelles protéines hétérodimères |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
EP3116909B1 (fr) | 2014-03-14 | 2019-11-13 | Novartis Ag | Molécules d'anticorps anti-lag-3 et leurs utilisations |
SG10202008629XA (en) | 2014-03-28 | 2020-10-29 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
KR102433464B1 (ko) | 2014-05-28 | 2022-08-17 | 아게누스 인코포레이티드 | 항-gitr 항체 및 이의 사용 방법 |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
EP3925622A1 (fr) | 2014-09-13 | 2021-12-22 | Novartis AG | Polythérapies |
CA2963281A1 (fr) * | 2014-10-03 | 2016-04-07 | Novartis Ag | Polytherapies |
EP4245376A3 (fr) | 2014-10-14 | 2023-12-13 | Novartis AG | Molécules d'anticorps de pd-l1 et leurs utilisations |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
JP2017536830A (ja) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3及びcd38に結合するヘテロ二量体抗体 |
IL252480B2 (en) | 2014-11-26 | 2023-12-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and tumor antigens |
EP3237449A2 (fr) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Anticorps trispécifiques |
MA42043A (fr) | 2015-05-07 | 2018-03-14 | Agenus Inc | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci |
US10144779B2 (en) | 2015-05-29 | 2018-12-04 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
KR20180036974A (ko) * | 2015-07-16 | 2018-04-10 | 바이오엑셀 테라퓨틱스 인코포레이티드 | 면역조절을 이용하는 암의 치료를 위한 신규한 접근법 |
IL297090A (en) | 2015-07-30 | 2022-12-01 | Macrogenics Inc | Molecules that bind pd-1 and methods of using them |
WO2017055404A1 (fr) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anticorps bispécifiques spécifiques de pd1 et tim3 |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
CN116063542A (zh) | 2015-12-02 | 2023-05-05 | 阿吉纳斯公司 | 抗体和其使用方法 |
US11623957B2 (en) | 2015-12-07 | 2023-04-11 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
TWI758267B (zh) | 2015-12-14 | 2022-03-21 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
RU2018123481A (ru) | 2015-12-16 | 2020-01-20 | Мерк Шарп И Доум Корп. | Анти-lag3 антитела и антигенсвязывающие фрагменты |
CN109415734B (zh) * | 2016-02-26 | 2022-08-19 | 西安大略大学 | 抗CD11d抗体及其用途 |
AU2017247008B2 (en) | 2016-04-06 | 2022-04-07 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
LT3458478T (lt) * | 2016-05-18 | 2021-02-10 | Boehringer Ingelheim International Gmbh | Antikūnai prieš pd-1 ir lag-3, skirti vėžio gydymui |
SG10201912563XA (en) | 2016-05-27 | 2020-02-27 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
WO2017218533A1 (fr) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Méthodes et procédés pour favoriser la fonction des cellules immunitaires |
IL263542B1 (en) | 2016-06-14 | 2024-06-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
US11214618B2 (en) | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | LAG-3 binding members |
EP3471754A1 (fr) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anticorps anti-pd-l1 |
CA3027612A1 (fr) | 2016-06-20 | 2017-12-28 | F-Star Delta Limited | Molecules de liaison liant pd-l1 et lag -3 |
ES2915410T3 (es) * | 2016-06-23 | 2022-06-22 | Jiangsu Hengrui Medicine Co | Anticuerpo contra LAG-3, fragmento de unión a antígeno del mismo y aplicación farmacéutica del mismo |
WO2018005706A1 (fr) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Anticorps hétérodimériques qui se lient au récepteur 2 de la somatostatine |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
NL2017270B1 (en) * | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
KR102340687B1 (ko) * | 2016-08-15 | 2021-12-16 | 국립대학법인 홋가이도 다이가쿠 | 항 lag-3 항체 |
PT3347379T (pt) | 2016-08-17 | 2020-02-18 | Compugen Ltd | Anticorpos anti-tígitos, anticorpos anti-pvrig e as suas combinações |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US20190202911A1 (en) * | 2016-09-08 | 2019-07-04 | Daiichi Sankyo Company, Limited | Antibody for treating autoimmune diseases |
KR20230133934A (ko) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
MX2019004241A (es) * | 2016-10-13 | 2019-08-05 | Symphogen As | Composiciones y anticuerpos anti-gen 3 de activacion de linfocitos (lag-3). |
AU2017342559B2 (en) | 2016-10-14 | 2022-03-24 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments |
AU2017347809A1 (en) * | 2016-10-28 | 2019-05-09 | Merck Sharp & Dohme Llc | Purification process for removal of tyrosine sulfation antibody variants; purified compositions |
CA3041340A1 (fr) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anticorps anti-ox40, anticorps anti-gitr, et leurs procedes d'utilisation |
WO2018094275A1 (fr) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases |
MX2019006340A (es) | 2016-12-07 | 2019-11-07 | Agenus Inc | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos. |
CN108204958A (zh) * | 2016-12-19 | 2018-06-26 | 伊缪泰普有限公司 | 结合测定 |
US20200121719A1 (en) * | 2017-01-06 | 2020-04-23 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
SG11201907208XA (en) | 2017-02-10 | 2019-09-27 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
KR20190120782A (ko) | 2017-02-20 | 2019-10-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
KR102236259B1 (ko) | 2017-02-22 | 2021-04-06 | 아이-맵 바이오파마 유에스 리미티드 | 항-lag-3 항체 및 그것의 사용 |
UA125700C2 (uk) | 2017-04-03 | 2022-05-18 | Ф. Хоффманн-Ля Рош Аг | Імунокон'югати антитіла до pd-1 з мутантом il-2 |
PE20191741A1 (es) | 2017-04-05 | 2019-12-12 | Symphogen As | Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 |
SG11201909154SA (en) | 2017-04-05 | 2019-10-30 | Hoffmann La Roche | Bispecific antibodies specifically binding to pd1 and lag3 |
EP3606954B1 (fr) * | 2017-04-05 | 2022-07-20 | F. Hoffmann-La Roche AG | Anticorps anti-lag3 |
TWI796329B (zh) * | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗-ilt4抗體及抗原結合片段 |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
US11845798B2 (en) * | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
CN110621337B (zh) * | 2017-05-10 | 2021-11-09 | 浙江时迈药业有限公司 | 抗lag3人单克隆抗体及其用途 |
MX2019012076A (es) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). |
MX2019012038A (es) | 2017-05-30 | 2019-11-18 | Bristol Myers Squibb Co | Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico. |
AU2018277824A1 (en) | 2017-05-30 | 2019-10-17 | Bristol-Myers Squibb Company | Treatment of LAG-3 positive tumors |
CA3065836A1 (fr) * | 2017-06-05 | 2018-12-13 | The Council Of The Queensland Institute Of Medical Research | Agents pour le traitement ou la prevention du cancer et utilisations correspondantes |
WO2018229715A1 (fr) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants |
PE20200717A1 (es) | 2017-06-22 | 2020-07-21 | Novartis Ag | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas |
WO2018235056A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer |
JP2020524694A (ja) | 2017-06-22 | 2020-08-20 | ノバルティス アーゲー | がんの処置における使用のためのIL−1β結合性抗体 |
EP3645037A1 (fr) | 2017-06-27 | 2020-05-06 | Novartis AG | Régimes posologiques pour anticorps anti-tim3 et leurs utilisations |
KR20200037250A (ko) | 2017-07-06 | 2020-04-08 | 메뤼스 엔.페. | 세포에 의해 발현되는 생물학적 활성을 조절하는 항체 |
EP3652212A4 (fr) * | 2017-07-13 | 2021-04-14 | Nanjing Leads Biolabs Co., Ltd. | Anticorps de liaison à lag-3 et leurs utilisations |
US20200172617A1 (en) | 2017-07-20 | 2020-06-04 | Novartis Ag | Dosage regimens of anti-lag-3 antibodies and uses thereof |
JP2020536495A (ja) * | 2017-08-30 | 2020-12-17 | フェインズ セラピューティクス,インコーポレーテッド | 抗lag−3抗体及びその使用 |
JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン |
WO2019081983A1 (fr) | 2017-10-25 | 2019-05-02 | Novartis Ag | Anticorps ciblant cd32b et leurs procédés d'utilisation |
CA3082383A1 (fr) * | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Anticorps bispecifiques et monospecifiques utilisant de nouvelles sequences anti-pd-1 |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
MX2020005128A (es) | 2017-11-17 | 2020-07-27 | Merck Sharp & Dohme | Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos. |
BR112020010579A2 (pt) | 2017-11-30 | 2020-11-10 | Novartis Ag | receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo |
WO2019121906A1 (fr) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Séquences de liaison spécifiques à pd-l1 insérées dans un domaine ch3 |
US11319355B2 (en) | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
CN111356476B (zh) * | 2017-12-22 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | Lag-3抗体药物组合物及其用途 |
CN109970857B (zh) | 2017-12-27 | 2022-09-30 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
WO2019129136A1 (fr) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anticorps anti-pd-l1 et ses applications |
WO2019129137A1 (fr) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anticorps anti-lag-3 et utilisations associées |
CN112218651A (zh) | 2018-01-08 | 2021-01-12 | 诺华公司 | 用于与嵌合抗原受体疗法组合的免疫增强rna |
CN111542546B (zh) * | 2018-01-18 | 2022-08-16 | 四川科伦博泰生物医药股份有限公司 | 抗lag-3抗体及其用途 |
CN108085393B (zh) * | 2018-01-31 | 2020-06-02 | 青岛泱深生物医药有限公司 | 肾透明细胞癌相关生物标志物及其应用 |
AU2019215031A1 (en) | 2018-01-31 | 2020-08-20 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
WO2019148412A1 (fr) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anticorps bispécifiques anti-pd-1/lag3 |
WO2019152574A1 (fr) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Procédés de traitement du cancer ou d'une infection à l'aide d'une combinaison d'un anticorps anti-pd -1, d'un anticorps anti-lag3 et d'un anticorps anti-tigit |
AU2019218136A1 (en) | 2018-02-08 | 2020-08-13 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
WO2019160956A1 (fr) | 2018-02-13 | 2019-08-22 | Novartis Ag | Thérapie par récepteur antigénique chimérique en combinaison avec il-15 r et il15 |
GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
JP7438180B2 (ja) * | 2018-03-20 | 2024-02-26 | ウーシー バイオロジクス アイルランド リミテッド | 新規抗lag-3抗体ポリペプチド |
CN110305215B (zh) * | 2018-03-20 | 2023-11-03 | 基石药业 | 新型抗lag-3抗体多肽 |
CN111918873A (zh) | 2018-03-27 | 2020-11-10 | 百时美施贵宝公司 | 使用紫外线信号实时监测滴度 |
EP3774917A4 (fr) * | 2018-03-30 | 2022-01-19 | Nanjing Legend Biotech Co., Ltd. | Anticorps à domaine unique contre lag-3 et leurs utilisations |
JP7104458B2 (ja) | 2018-04-02 | 2022-07-21 | 上海博威生物医薬有限公司 | リンパ球活性化遺伝子-3(lag-3)結合抗体およびその使用 |
WO2019195408A1 (fr) * | 2018-04-03 | 2019-10-10 | Dragonfly Therapeutics, Inc. | Domaines variables d'anticorps ciblant les dll3, et leur utilisation |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
JP2021521784A (ja) | 2018-04-18 | 2021-08-30 | ゼンコア インコーポレイテッド | IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用 |
US11505595B2 (en) | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
KR20210005894A (ko) * | 2018-05-03 | 2021-01-15 | 상하이 에피맙 바이오테라퓨틱스 컴퍼니, 리미티드 | Pd-1 및 lag-3에 대한 높은 친화성 항체 및 이로부터 제조된 이중특이성 결합 단백질 |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
BR112020024351A2 (pt) | 2018-06-01 | 2021-02-23 | Novartis Ag | moléculas de ligação contra bcma e usos das mesmas |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
CR20210001A (es) | 2018-07-10 | 2021-04-19 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteina con dedos de zinc 2 de la familia ikaros (1kzf2) |
WO2020021465A1 (fr) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Procédé de traitement de tumeurs neuroendocrines |
MX2021000726A (es) | 2018-07-26 | 2021-03-25 | Bristol Myers Squibb Co | Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer. |
US20220363763A1 (en) * | 2018-08-21 | 2022-11-17 | Abl Bio Inc. | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof |
AU2019337547A1 (en) * | 2018-09-13 | 2021-03-18 | Merck Sharp & Dohme Llc | Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer |
WO2020072821A2 (fr) | 2018-10-03 | 2020-04-09 | Xencor, Inc. | Protéines de fusion fc hétérodimères d'il -12 |
KR20210080437A (ko) | 2018-10-19 | 2021-06-30 | 브리스톨-마이어스 스큅 컴퍼니 | 흑색종을 위한 조합 요법 |
WO2020089811A1 (fr) | 2018-10-31 | 2020-05-07 | Novartis Ag | Conjugué médicament-anticorps anti-dc-sign |
BR112021008679A8 (pt) * | 2018-11-05 | 2023-04-11 | Merck Sharp & Dohme | Métodos para tratar câncer, e composição farmacêutica |
WO2020097139A1 (fr) * | 2018-11-07 | 2020-05-14 | Merck Sharp & Dohme Corp. | Co-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1 |
EP3890749A4 (fr) | 2018-12-04 | 2022-08-03 | Sumitomo Dainippon Pharma Oncology, Inc. | Inhibiteurs de cdk9 et leurs polymorphes destinés à être utilisés en tant qu'agents pour le traitement du cancer |
KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
JP2022516850A (ja) | 2018-12-21 | 2022-03-03 | ノバルティス アーゲー | 骨髄異形成症候群の治療又は予防におけるIL-1β抗体の使用 |
AU2019409139A1 (en) | 2018-12-21 | 2021-06-03 | Novartis Ag | Use of IL-1β binding antibodies |
WO2020128637A1 (fr) | 2018-12-21 | 2020-06-25 | Novartis Ag | UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H |
WO2020128613A1 (fr) | 2018-12-21 | 2020-06-25 | Novartis Ag | Utilisation d'anticorps de liaison à il-1bêta |
AU2019408408A1 (en) | 2018-12-21 | 2021-06-03 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
KR20210146290A (ko) | 2019-02-12 | 2021-12-03 | 스미토모 다이니폰 파마 온콜로지, 인크. | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 |
US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EP3924055B1 (fr) | 2019-02-15 | 2024-04-03 | Novartis AG | Dérivés de 3-(1-oxoisoindoline-2-yl)pipéridine-2,6-dione substitués et leurs utilisations |
WO2020172658A1 (fr) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Procédés d'isolement d'une protéine |
SG11202109406TA (en) | 2019-03-01 | 2021-09-29 | Xencor Inc | Heterodimeric antibodies that bind enpp3 and cd3 |
US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
WO2020198077A1 (fr) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant |
WO2020216383A1 (fr) * | 2019-04-26 | 2020-10-29 | Single Cell Technology, Inc. | Anticorps anti-lag -3 |
WO2020236667A1 (fr) * | 2019-05-17 | 2020-11-26 | Gb006, Inc. | Procédés de traitement du cancer |
JP2022533711A (ja) * | 2019-05-22 | 2022-07-25 | レイドス, インコーポレイテッド | Lag3結合ペプチド |
WO2020237221A1 (fr) | 2019-05-23 | 2020-11-26 | Bristol-Myers Squibb Company | Méthodes de surveillance de milieu |
KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
WO2020243568A1 (fr) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet approprié pour une thérapie d'immuno-oncologie (i-o) |
CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
CN114302878A (zh) | 2019-07-03 | 2022-04-08 | 大日本住友制药肿瘤公司 | 酪氨酸激酶非受体1(tnk1)抑制剂及其用途 |
CA3139314A1 (fr) * | 2019-07-17 | 2021-01-21 | Noxopharm Limited | Therapie immuno-oncologique a l'aide de composes d'isoflavone |
US20220251194A1 (en) * | 2019-07-30 | 2022-08-11 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3/tigit trispecific antibodies and anti-pd-1/lag3 bicpecific antibodies |
WO2021024020A1 (fr) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer |
CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
JP2022549273A (ja) | 2019-09-22 | 2022-11-24 | ブリストル-マイヤーズ スクイブ カンパニー | Lag-3アンタゴニスト治療のための定量的空間プロファイリング |
WO2021079195A1 (fr) | 2019-10-21 | 2021-04-29 | Novartis Ag | Inhibiteurs de tim-3 et leurs utilisations |
BR112022007376A2 (pt) | 2019-10-21 | 2022-07-05 | Novartis Ag | Terapias de combinação com venetoclax e inibidores de tim-3 |
WO2021092221A1 (fr) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle |
WO2021092220A1 (fr) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle |
KR20220093349A (ko) | 2019-11-08 | 2022-07-05 | 브리스톨-마이어스 스큅 컴퍼니 | 흑색종에 대한 lag-3 길항제 요법 |
US20220387417A1 (en) * | 2019-11-11 | 2022-12-08 | Cstone Pharmaceuticals (Suzhou) Co., Ltd. | Pharmaceutical Combination and Use Thereof |
WO2021123996A1 (fr) | 2019-12-20 | 2021-06-24 | Novartis Ag | Utilisations d'anticorps anti-tgf-bêtas et inhibiteurs de point de contrôle pour le traitement des maladies prolifératives |
US20230333090A1 (en) * | 2019-12-20 | 2023-10-19 | Merck Sharp & Dohme Llc | Lag3 antagonist cell based potency assay |
JP2023510393A (ja) | 2020-01-17 | 2023-03-13 | ノバルティス アーゲー | 骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのtim-3阻害剤と低メチル化剤とを含む組合せ |
AU2021210029A1 (en) * | 2020-01-21 | 2022-09-01 | Shanghai Henlius Biopharmaceutical Co., Ltd. | Anti-LAG3 monoclonal antibody, and preparation method therefor and use thereof |
AU2021213153A1 (en) * | 2020-01-29 | 2022-08-04 | Merck Sharp & Dohme Llc | Methods of separating host cell lipases from an anti-LAG3 antibody production |
JP2023514152A (ja) | 2020-02-06 | 2023-04-05 | ブリストル-マイヤーズ スクイブ カンパニー | Il-10およびその使用 |
KR102245082B1 (ko) * | 2020-02-14 | 2021-04-26 | 단국대학교 천안캠퍼스 산학협력단 | 치주인대전구세포 표면에 특이적으로 결합하는 두 가지 IgG 타입 단일클론항체 LG43, LG73 및 그의 용도 |
AU2021247415A1 (en) | 2020-03-30 | 2022-09-29 | Noxopharm Limited | Methods for the treatment of inflammation associated with infection |
US20230167166A1 (en) * | 2020-04-24 | 2023-06-01 | Memorial Sloan Kettering Cancer Center | Targeted therapy for the treatment & prevention of life-threatening complications of infection |
WO2021231976A1 (fr) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3 |
CA3185657A1 (fr) | 2020-06-04 | 2021-12-09 | Leidos, Inc. | Composes immunomodulateurs |
CN114605544B (zh) * | 2020-06-05 | 2023-08-01 | 北京天广实生物技术股份有限公司 | Lag3抗体及其用途 |
AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
AU2021306613A1 (en) | 2020-07-07 | 2023-02-02 | BioNTech SE | Therapeutic RNA for HPV-positive cancer |
CA3189692A1 (fr) | 2020-07-31 | 2022-02-03 | Leidos, Inc. | Peptides se liant a lag3 |
US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | ANTI–CD28 COMPOSITIONS |
AU2021331476A1 (en) | 2020-08-28 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
WO2022043557A1 (fr) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Méthode de traitement de cancers exprimant le psma |
US20230303700A1 (en) | 2020-08-31 | 2023-09-28 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
JP2023544410A (ja) | 2020-10-05 | 2023-10-23 | ブリストル-マイヤーズ スクイブ カンパニー | タンパク質を濃縮するための方法 |
JP2023548051A (ja) | 2020-10-23 | 2023-11-15 | ブリストル-マイヤーズ スクイブ カンパニー | 肺がんのためのlag-3アンタゴニスト療法 |
KR20230104651A (ko) | 2020-11-06 | 2023-07-10 | 노파르티스 아게 | Cd19 결합 분자 및 이의 용도 |
WO2022109987A1 (fr) * | 2020-11-27 | 2022-06-02 | Shanghai Benemae Pharmaceutical Corporation | Nouveaux anticorps anti-lag3, leurs procédés de préparation et d'utilisation |
US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
WO2022120179A1 (fr) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Signatures géniques multi-tumorales et leurs utilisations |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
CN116514971B (zh) * | 2020-12-10 | 2023-10-27 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
WO2022135666A1 (fr) | 2020-12-21 | 2022-06-30 | BioNTech SE | Programme de traitement faisant intervenir des protéines cytokines |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (fr) | 2020-12-21 | 2022-06-30 | BioNTech SE | Arn thérapeutique pour le traitement du cancer |
EP4267105A1 (fr) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Compositions d'anticorps et leurs procédés d'utilisation |
EP4267172A1 (fr) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Administration sous-cutanée d'anticorps pd1/pd-l1 |
WO2022189936A1 (fr) * | 2021-03-08 | 2022-09-15 | Medimmune, Llc | Anticorps dirigés contre gdf-15 |
CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Cd3及びgpc3に結合するヘテロ二量体抗体 |
IL307262A (en) | 2021-03-29 | 2023-11-01 | Juno Therapeutics Inc | METHODS FOR DOSAGE AND THERAPY IN COMBINATION OF CHECKPOINT INHIBITOR AND CAR T CELL THERAPY |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
WO2022240741A1 (fr) | 2021-05-12 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Agents inhibiteurs de lag3 et gal3, peptides xbp1, cs1 et cd138, et leurs méthodes d'utilisation |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
CN115403670A (zh) | 2021-05-26 | 2022-11-29 | 安徽瀚海博兴生物技术有限公司 | 抗cd40抗体及其用途 |
WO2023285552A1 (fr) | 2021-07-13 | 2023-01-19 | BioNTech SE | Agents de liaison multispécifiques contre cd40 et cd137 en polythérapie du cancer |
CN115611983A (zh) | 2021-07-14 | 2023-01-17 | 三优生物医药(上海)有限公司 | Cldn18.2结合分子及其用途 |
CN118103058A (zh) * | 2021-08-17 | 2024-05-28 | 狼人治疗公司 | 诱导型il-2和pd-1/pd-l1组合疗法 |
CN115873116A (zh) * | 2021-09-29 | 2023-03-31 | 中山康方生物医药有限公司 | 抗lag3抗体、药物组合物及用途 |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
CA3224890A1 (fr) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Therapie par antagoniste de lag-3 pour cancer hematologique |
WO2023072294A1 (fr) * | 2021-11-01 | 2023-05-04 | Elpiscience (Suzhou) Biopharma, Ltd. | Nouveaux anticorps anti-lag3 |
WO2023111203A1 (fr) | 2021-12-16 | 2023-06-22 | Onxeo | Nouvelles molécules d'acide nucléique conjuguées et leurs utilisations |
WO2023147371A1 (fr) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Polythérapie pour carcinome hépatocellulaire |
WO2023161350A1 (fr) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Administration nucléotidique d'une thérapie anticancéreuse |
WO2023164638A1 (fr) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Polythérapie pour carcinome colorectal |
WO2023168404A1 (fr) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Méthodes de traitement d'une tumeur |
WO2023170606A1 (fr) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Utilisation d'anticorps anti-claudine-1 pour augmenter la disponibilité des lymphocytes t |
WO2023173011A1 (fr) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Expression transitoire de protéines thérapeutiques |
WO2023178192A1 (fr) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Anticorps antagonistes de l'il-18bp et leur utilisation en monothérapie et polythérapie dans le traitement du cancer |
WO2023178329A1 (fr) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Procédés d'isolement de polypeptides |
CN114634574B (zh) * | 2022-04-18 | 2022-12-20 | 先进生物(苏州)有限公司 | 抗B7H6的scFv抗体、其编码基因及其应用 |
WO2023214325A1 (fr) | 2022-05-05 | 2023-11-09 | Novartis Ag | Dérivés de pyrazolopyrimidine et leurs utilisations en tant qu'inhibiteurs de tet2 |
WO2023235847A1 (fr) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Compositions d'anticorps et leurs procédés d'utilisation |
WO2024102603A1 (fr) * | 2022-11-07 | 2024-05-16 | Merck Sharp & Dohme Llc | Conjugaison pontée par glycane bisécant pour la production de conjugués de glycoprotéines |
WO2024116140A1 (fr) | 2022-12-01 | 2024-06-06 | Medimmune Limited | Polythérapie comprenant des anticorps anti-pd-l1 et anti-cd73 pour le traitement du cancer |
WO2024126457A1 (fr) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et des inhibiteurs de point de contrôle immunitaire |
Family Cites Families (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946A (en) | 1847-01-26 | Improvement in carriage-wheels | ||
US778A (en) | 1838-06-12 | Thomas wright | ||
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
EP0154316B1 (fr) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Lymphokine chimiquement modifiée et son procédé de préparation |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
EP0307434B2 (fr) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Anticorps alteres |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992003918A1 (fr) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Animaux non humains transgeniques capables de produire des anticorps heterologues |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
DK0656946T4 (da) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
DK0758383T3 (da) | 1994-05-06 | 2007-05-29 | Roussy Inst Gustave | Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof |
US5532210A (en) | 1994-06-08 | 1996-07-02 | E. I. Du Pont De Nemours And Company | High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
ATE227586T1 (de) | 1995-07-21 | 2002-11-15 | Applied Research Systems | Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein |
CA2273080C (fr) | 1996-11-28 | 2004-11-09 | Institut Gustave Roussy | Mutants de la proteine lag-3, leur expression et utilisation |
IL130168A (en) | 1996-11-29 | 2006-09-05 | Serono Lab | Genetically engineered cells containing LAG-3-expressing DNA and their use |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
EP0900841A1 (fr) | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Variantes d'épissure de LAG-3 |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
US6329511B1 (en) | 1998-12-01 | 2001-12-11 | Protein Design Labs, Inc. | Humanized antibodies to γ-interferon |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
AU7684201A (en) | 2000-06-28 | 2002-01-08 | Glycofi Inc | Methods for producing modified glycoproteins |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
US7795002B2 (en) | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
ES2367891T3 (es) | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
SE0103423D0 (sv) | 2001-10-12 | 2001-10-12 | Astrazeneca Ab | Polymorphism |
AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
AU2004217526B2 (en) * | 2003-02-28 | 2010-02-04 | St. Jude Children's Research Hospital Inc. | T cell regulation |
US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
PE20090046A1 (es) | 2003-11-10 | 2009-01-26 | Schering Corp | Anticuerpo recombinante humanizado anti-interleuquina 10 |
WO2005120571A2 (fr) | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Procede d'immunisation passive contre des maladies ou des troubles caracterise(e)s par agregation amyloide a risque diminue de neuroinflammation |
BRPI0715917A2 (pt) | 2006-08-11 | 2014-11-25 | Schering Corp | Anticorpos para il-17a |
KR20090088950A (ko) | 2006-12-14 | 2009-08-20 | 쉐링 코포레이션 | 가공된 항-tslp 항체 |
US9244059B2 (en) * | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP1987839A1 (fr) * | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes |
AU2008266951B2 (en) | 2007-06-18 | 2013-12-12 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor PD-1 |
EP2044949A1 (fr) | 2007-10-05 | 2009-04-08 | Immutep | Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes |
AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
NZ602166A (en) * | 2008-11-25 | 2014-02-28 | Alder Biopharmaceuticals Inc | Antibodies to il-6 and use thereof |
UA105198C2 (ru) * | 2008-12-12 | 2014-04-25 | Берингер Ингельхайм Интернациональ Гмбх | Антитело против инсулиноподобных факторов роста |
DK2542590T4 (da) | 2010-03-05 | 2020-07-13 | Univ Johns Hopkins | Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner |
WO2012004367A1 (fr) | 2010-07-09 | 2012-01-12 | N.V. Organon | Anticorps agoniste de cd27 |
CN103796680A (zh) | 2011-06-21 | 2014-05-14 | 约翰霍普金斯大学 | 用于增强针对赘生物的基于免疫的治疗的聚焦放射 |
HUE040455T2 (hu) | 2011-06-30 | 2019-03-28 | Genzyme Corp | T-sejt aktiválás inhibitorai |
CN104011076A (zh) | 2011-10-31 | 2014-08-27 | 默沙东公司 | 用于制备具有改善性能的抗体的方法 |
WO2013066765A1 (fr) | 2011-11-01 | 2013-05-10 | Merck Sharp & Dohme Corp. | Mutation de tup1 dans de la levure glycomodifiée |
GB201120527D0 (en) | 2011-11-29 | 2012-01-11 | Ucl Business Plc | Method |
US20150132272A1 (en) | 2012-06-18 | 2015-05-14 | Yale University | Compositions and methods for diminishing an immune response |
UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
CA2874864C (fr) | 2012-08-14 | 2023-02-21 | Ibc Pharmaceuticals, Inc. | Anticorps bispecifiques rediriges contre des cellules t pour le traitement de maladies |
AU2013304627A1 (en) | 2012-08-21 | 2015-02-26 | Glaxo Group Limited | Compositions comprising a single variable domain and camostat mesylate (CM) |
KR20150043343A (ko) | 2012-08-21 | 2015-04-22 | 글락소 그룹 리미티드 | 항체 및 카모스타트 메실레이트 (cm)를 포함하는 조성물 |
CN105102480B (zh) * | 2012-12-24 | 2019-04-16 | 艾伯维公司 | 催乳素受体结合蛋白及其用途 |
US10280221B2 (en) | 2013-03-15 | 2019-05-07 | Glaxosmithkline Intellectual Property Development Limited | Anti-LAG-3 binding proteins |
ES2779398T3 (es) | 2013-03-15 | 2020-08-17 | Dana-Farber Cancer Institute Inc | Péptidos terapéuticos |
CN107252485A (zh) | 2013-04-03 | 2017-10-17 | Ibc药品公司 | 用于诱导对疾病的免疫应答的组合疗法 |
AU2014259719B2 (en) | 2013-05-02 | 2019-10-03 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
WO2014209804A1 (fr) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Anticorps bispécifiques |
JP2016531907A (ja) | 2013-08-02 | 2016-10-13 | アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. | 免疫刺激のためのcd27アゴニストと免疫チェックポイント阻害との組み合わせ |
EP3508502B1 (fr) | 2013-09-20 | 2023-04-26 | Bristol-Myers Squibb Company | Combinaison d'anticorps anti-lag-3 et anti-pd-1 pour traiter des tumeurs |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
EP3065772A4 (fr) | 2013-11-05 | 2017-09-13 | Cognate Bioservices, Inc. | Combinaisons d'inhibiteurs de point de contrôle et d'agents thérapeutiques pour traiter un cancer |
US20160271239A1 (en) | 2013-11-05 | 2016-09-22 | Bavarian Nordic A/S | Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor |
JP6705746B2 (ja) | 2013-12-06 | 2020-06-03 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 治療用ペプチド |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
EP3096782A4 (fr) | 2014-01-21 | 2017-07-26 | Medlmmune, LLC | Compositions et procédés pour moduler et réorienter des réponses immunitaires |
HRP20212033T1 (hr) | 2014-01-28 | 2022-04-01 | Bristol-Myers Squibb Company | Anti-lag-3 antitijela za liječenje hematoloških maligniteta |
EP3116909B1 (fr) | 2014-03-14 | 2019-11-13 | Novartis Ag | Molécules d'anticorps anti-lag-3 et leurs utilisations |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
EP3160497A4 (fr) | 2014-06-27 | 2018-01-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Conjugués pour immunothérapie |
JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
US11116838B2 (en) | 2015-01-29 | 2021-09-14 | The Trustees Of The University Of Pennsylvania | Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy |
MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
KR20170138477A (ko) | 2015-04-17 | 2017-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
CN114853891A (zh) | 2015-07-22 | 2022-08-05 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
WO2019148412A1 (fr) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anticorps bispécifiques anti-pd-1/lag3 |
-
2015
- 2015-08-11 JO JOP/2015/0192A patent/JO3663B1/ar active
- 2015-08-17 CR CR20170059A patent/CR20170059A/es unknown
- 2015-08-17 JP JP2017528771A patent/JP2017532059A/ja active Pending
- 2015-08-17 LT LTEP15753877.8T patent/LT3182999T/lt unknown
- 2015-08-17 AU AU2015305770A patent/AU2015305770B2/en active Active
- 2015-08-17 PE PE2017000228A patent/PE20170288A1/es unknown
- 2015-08-17 MX MX2017002230A patent/MX2017002230A/es active IP Right Grant
- 2015-08-17 IL IL297053A patent/IL297053A/en unknown
- 2015-08-17 PL PL15753877T patent/PL3182999T3/pl unknown
- 2015-08-17 EP EP20214920.9A patent/EP3834842A1/fr active Pending
- 2015-08-17 MA MA40476A patent/MA40476B1/fr unknown
- 2015-08-17 MY MYPI2017000223A patent/MY187262A/en unknown
- 2015-08-17 GE GEAP201514453A patent/GEP20227343B/en unknown
- 2015-08-17 MD MDA20170031A patent/MD4716C1/ro active IP Right Grant
- 2015-08-17 AP AP2017009763A patent/AP2017009763A0/en unknown
- 2015-08-17 CN CN201580056806.5A patent/CN107001470B/zh active Active
- 2015-08-17 CA CA2957275A patent/CA2957275C/fr active Active
- 2015-08-17 SG SG11201701090VA patent/SG11201701090VA/en unknown
- 2015-08-17 US US15/305,011 patent/US20170290914A1/en not_active Abandoned
- 2015-08-17 KR KR1020197031113A patent/KR102321166B1/ko active IP Right Grant
- 2015-08-17 PT PT157538778T patent/PT3182999T/pt unknown
- 2015-08-17 UA UAA201901575A patent/UA127888C2/uk unknown
- 2015-08-17 KR KR1020177007118A patent/KR102037197B1/ko active IP Right Grant
- 2015-08-17 UA UAA201702455A patent/UA119571C2/uk unknown
- 2015-08-17 EP EP15753877.8A patent/EP3182999B1/fr active Active
- 2015-08-17 SI SI201531525T patent/SI3182999T1/sl unknown
- 2015-08-17 BR BR112017003194A patent/BR112017003194B8/pt active IP Right Grant
- 2015-08-17 CA CA3082655A patent/CA3082655A1/fr not_active Abandoned
- 2015-08-17 RS RS20210287A patent/RS61559B1/sr unknown
- 2015-08-17 ES ES15753877T patent/ES2857505T3/es active Active
- 2015-08-17 HU HUE15753877A patent/HUE053641T2/hu unknown
- 2015-08-17 DK DK15753877.8T patent/DK3182999T3/da active
- 2015-08-17 TN TN2017000025A patent/TN2017000025A1/en unknown
- 2015-08-17 MA MA055347A patent/MA55347A/fr unknown
- 2015-08-17 WO PCT/US2015/045481 patent/WO2016028672A1/fr active Application Filing
- 2015-08-18 TW TW104126866A patent/TWI673286B/zh active
- 2015-08-18 TW TW108102061A patent/TWI698448B/zh active
- 2015-08-18 TW TW108123466A patent/TWI742395B/zh active
-
2017
- 2017-02-07 CL CL2017000311A patent/CL2017000311A1/es unknown
- 2017-02-07 ZA ZA2017/00956A patent/ZA201700956B/en unknown
- 2017-02-12 IL IL250566A patent/IL250566B2/en unknown
- 2017-02-16 PH PH12017500297A patent/PH12017500297A1/en unknown
- 2017-02-17 CO CONC2017/0001558A patent/CO2017001558A2/es unknown
- 2017-02-17 MX MX2019005426A patent/MX2019005426A/es unknown
- 2017-02-17 DO DO2017000047A patent/DOP2017000047A/es unknown
- 2017-02-17 NI NI201700018A patent/NI201700018A/es unknown
- 2017-02-17 GT GT201700034A patent/GT201700034A/es unknown
- 2017-04-07 US US15/482,355 patent/US10188730B2/en active Active
-
2018
- 2018-07-26 JP JP2018140501A patent/JP6538247B2/ja active Active
- 2018-12-04 US US16/209,381 patent/US10898571B2/en active Active
- 2018-12-05 US US16/210,140 patent/US11278620B2/en active Active
- 2018-12-07 US US16/213,443 patent/US11207406B2/en active Active
- 2018-12-12 AU AU2018278910A patent/AU2018278910A1/en not_active Abandoned
-
2019
- 2019-04-01 JP JP2019069725A patent/JP6843174B2/ja active Active
-
2020
- 2020-06-22 ZA ZA2020/03742A patent/ZA202003742B/en unknown
- 2020-09-08 AU AU2020230256A patent/AU2020230256B2/en active Active
-
2021
- 2021-03-03 HR HRP20210372TT patent/HRP20210372T1/hr unknown
- 2021-03-24 CY CY20211100263T patent/CY1124252T1/el unknown
-
2022
- 2022-02-11 US US17/669,891 patent/US20220257762A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43576A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
MA55347A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
MA44776A (fr) | Anticorps anti-vista humain et leur utilisation | |
ZA201700528B (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
IL290457A (en) | Antibodies and their conjugates | |
MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
DK3458479T3 (da) | Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater | |
SG10201912199XA (en) | Anti-tim-3 antibodies and use thereof | |
IL258332A (en) | Antibody factors specific for human differentiation group 19 and their uses | |
DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
DK3504242T3 (da) | Anti-ox40-antistoffer og anvendelse deraf | |
MA55043A (fr) | Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20 | |
DK3307274T3 (da) | Anti-cd123-antistoffer og konjugater deraf | |
EP3541840C0 (fr) | Anti-hla-g anticorps et ses utilisation | |
MA41313A (fr) | Anticorps de liaison de la protéine april modifiés | |
MA42821A (fr) | Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci | |
DK3532499T3 (da) | ANTI-IL-33-antistoffer og anvendelser deraf | |
MA43738A (fr) | Anticorps anti-tnfalpha et leurs fragments fonctionnels | |
DK3402821T3 (da) | Psma-bindende antistof og anvendelser deraf | |
MA43717A (fr) | Anticorps anti-tnf et fragments fonctionnels de ceux-ci | |
MA53887A (fr) | Anticorps à liaison protofibrille a-bêta améliorée | |
MA44777A (fr) | Anticorps humanisés anti-basigine et leur utilisation |